亞太淋巴水腫治療市場規模、份額及趨勢分析報告-產業概況及2032年預測

请求目录 请求目录 与分析师交谈 与分析师交谈 免费样本报告 免费样本报告 购买前请咨询 提前咨询 立即购买 立即购买

亞太淋巴水腫治療市場規模、份額及趨勢分析報告-產業概況及2032年預測

  • Healthcare
  • Published Report
  • Dec 2021
  • Asia-Pacific
  • 350 页面
  • 桌子數: 224
  • 图号: 46
  • Author : Sachin Pawar

通过敏捷供应链咨询解决关税挑战

供应链生态系统分析现已成为 DBMR 报告的一部分

Asia Pacific Lymphedema Treatment Market

市场规模(十亿美元)

CAGR :  % Diagram

Chart Image USD 136.19 Million USD 350.22 Million 2024 2032
Diagram Forecast Period
2025 –2032
Diagram Market Size (Base Year)
USD 136.19 Million
Diagram Market Size (Forecast Year)
USD 350.22 Million
Diagram CAGR
%
Diagram Major Markets Players
  • Tactile Medical (U.S.)
  • Essity Aktiebolag (publ) (Sweden)
  • 3M (U.S.)
  • Cardinal Health (U.S.)
  • Lohmann & Rauscher GmbH & Co. KG

亞太淋巴水腫治療市場細分,依治療類型(壓迫療法、手術、藥物療法、雷射療法等)、類型(繼發性淋巴水腫和原發性淋巴水腫)、患處(下肢、上肢及生殖器)、年齡組(成人、老年及兒童)、給藥途徑(口服、注射及外用)、最終用戶(院內、專科診所、門診手術至 203 年市場(203 年)。

淋巴水腫治療市場

亞太淋巴水腫治療市場規模

  • 2024 年亞太淋巴水腫治療市場規模為1.3619 億美元 ,預計 到 2032 年將達到3.5022美元,預測期內複合年增長率為 12.80%。
  • 市場成長主要得益於全球淋巴水腫和癌症相關淋巴水腫盛行率的不斷上升,加上診斷影像方式和創新治療方法的重大技術進步,從而改善了對病情的識別和管理。
  • 此外,患者和臨床醫生對更有效、更便捷、更全面的慢性腫脹管理解決方案的需求日益增長,改善生活質量,這使得先進的壓迫療法、淋巴引流技術和顯微外科幹預成為淋巴水腫治療的現代標準。這些因素正在加速淋巴水腫管理解決方案的普及,顯著促進該行業的成長。

亞太淋巴水腫治療市場分析

  • 淋巴水腫的特徵是淋巴系統功能受損引起的慢性腫脹,由於其對患者生活品質有重大影響,通常是癌症治療或遺傳易感性的併發症,因此成為現代醫療保健中越來越重要的關注領域
  • 淋巴水腫治療需求不斷增長,主要原因是全球淋巴水腫和癌症相關淋巴水腫盛行率不斷上升、醫護人員和患者意識不斷增強,以及診斷和治療方法的技術不斷進步
  • 中國在淋巴水腫治療市場佔據主導地位,預計將成為複合年增長率 (CAGR) 最高的市場之一,這主要是由於人們對先進診斷和治療方式的認識和採用不斷提高,以及淋巴絲蟲病的高負擔和癌症發病率上升等因素,這些因素推動了對有效淋巴水腫管理解決方案的需求  
  • 2024 年,壓力療法佔據淋巴水腫治療市場的主導地位,這得益於其作為治療腫脹的一線和最常見治療方法的良好聲譽、其非侵入性,以及壓力服裝和設備的持續創新,從而提高了舒適度和療效

報告範圍和亞太淋巴水腫治療市場細分    

屬性

淋巴水腫治療關鍵市場洞察

涵蓋的領域

  • 依治療類型:壓迫療法、手術、藥物治療、雷射治療及其他
  • 依類型:繼發性淋巴水腫和原發性淋巴水腫
  • 依受影響部位:下肢、上肢和生殖器
  • 依年齡層:成人、老年人和兒童
  • 依給藥途徑:口服、注射及外用
  • 依最終用戶分類:醫院、專科診所、門診手術中心等
  • 按分銷管道:藥局、商店、直接投標及其他

覆蓋國家

 亞太

  • 中國
  • 日本
  • 印度
  • 韓國
  • 新加坡
  • 馬來西亞
  • 澳洲
  • 泰國
  • 印尼
  • 菲律賓
  • 亞太其他地區 

主要市場參與者

  • Tactile Medical(美國)
  • Essity Aktiebolag (publ)(瑞典)
  • 3M(美國)
  • 康德樂(美國)
  • Lohmann & Rauscher GmbH & Co. KG(德國)
  • PAUL HARTMANN AG(德國)
  • medi GmbH & Co. KG(德國)
  • 康維特公司(英國)
  • Juzo(德國)
  • Smith + Nephew(英國)
  • SIGVARIS集團(瑞士)
  • Sanyleg Srl(義大利)
  • Avet Pharmaceuticals Inc.(美國)
  • ThermoTek Inc.(美國)
  • Huntleigh Healthcare Limited(英國)
  • KOYA醫療(美國)
  • AIROS Medical, Inc.(美國)
  • 生物壓縮系統(美國)

市場機會

  • 與數位健康和​​遠端監控解決方案的集成
  • 新興市場需求不斷成長

加值資料資訊集

除了對市場價值、成長率、細分、地理覆蓋範圍和主要參與者等市場情景的洞察之外,Data Bridge Market Research 策劃的市場報告還包括深入的專家分析、定價分析、品牌份額分析、消費者調查、人口統計分析、供應鏈分析、價值鏈分析、原材料/消耗品概述、供應商選擇標準、PESTLE 分析、波特分析和監管框架。

亞太淋巴水腫治療市場趨勢

透過人工智慧和數位整合增強患者護理

  • 亞太地區淋巴水腫市場一個顯著且加速發展的趨勢是人工智慧(AI) 與數位健康平台的深度融合,涵蓋遠端監控、個人化治療演算法和遠距醫療解決方案。這種技術融合顯著提升了患者的便利性、治療順從性以及慢性病的整體管理。例如,該地區癌症發生率和其他導致淋巴水腫的慢性疾病負擔日益加重,凸顯出一個關鍵的患者群體正在推動對長期淋巴水腫管理解決方案的需求。
  • 人工智慧在淋巴水腫護理中的應用,可以實現多種功能,例如分析海量患者數據以預測潛在的病情復發、根據個體反應優化壓力服的壓力水平,以及提供更聰明的預警以促進早期幹預。例如,一些新興的人工智慧解決方案正在被探索,旨在透過分析影像資料來提高早期淋巴水腫檢測的準確性,並指導患者進行個人化的復健訓練。此外,整合通訊功能的數位平台為患者提供了便利的虛擬問診服務,使他們能夠遠端討論症狀並獲得指導。
  • 淋巴水腫監測設備和自我管理工具與更廣泛的數位健康生態系統的無縫集成,有助於集中控制患者護理的各個方面。透過單一介面,使用者可以管理肢體測量數據、治療依從性並與護理團隊溝通,從而創造統一且更主動的健康管理體驗。
  • 這種更聰明、直觀、互聯的淋巴水腫管理系統趨勢正在從根本上重塑患者對慢性病護理的期望。因此,各大公司正在開發人工智慧診斷工具和數位平台,這些工具和平台具備自動數據分析、個人化警報和遠端治療調整等功能。
  • 隨著臨床醫生和患者越來越重視對這種終身疾病的有效、便捷和全面的管理,對提供無縫 AI 和數位整合的淋巴水腫解決方案的需求在醫療保健環境和患者群體中迅速增長

司機

由於疾病盛行率上升和診斷能力增強,需求不斷增長

  • 亞太地區淋巴水腫盛行率不斷上升,尤其是癌症治療引起的繼發性淋巴水腫,加之診斷技術的加速進步和人們意識的不斷增強,是推動淋巴水腫管理解決方案需求成長的重要因素
  • 例如,亞太地區患者人數眾多且老化,加上慢性病發病率上升和醫療保健可近性的改善,顯著增加了對有效淋巴水腫管理的需求
  • 隨著醫療保健專業人員和患者越來越意識到未治療的淋巴水腫的長期影響並尋求早期幹預,生物阻抗譜 (BIS) 和複雜成像(例如 ICG 淋巴造影)等先進診斷工具可提供精確測量和早期檢測,與傳統捲尺測量相比具有顯著優勢
  • 此外,人們越來越重視以患者為中心的護理,並希望改善慢性病患者的生活質量,這使得綜合淋巴水腫管理成為癌症後護理和慢性病管理的一個組成部分,與康復計劃和支持療法無縫銜接
  • 早期診斷的便利性、數位健康工具提供的個人化治療方案以及透過先進的壓迫療法和運動療法進行自我管理症狀的能力,是推動淋巴水腫解決方案在臨床和家庭護理環境中廣泛應用的關鍵因素。主動篩檢的趨勢以及使用者友善自我管理產品的日益普及,進一步促進了市場的成長。

克制/挑戰

對診斷不足和高昂治療費用的擔憂

  • 淋巴水腫普遍存在漏診和誤診問題,加之持續治療帶來的沉重經濟負擔,對更廣泛的市場滲透和有效的患者護理構成了重大挑戰。由於淋巴水腫早期症狀隱匿,常被醫護人員忽視,導致幹預延誤和病情進展,加劇了患者對其長期健康狀況的擔憂。
  • 例如,在亞太地區的許多地區,持續的淋巴水腫護理需要大量的自付費用,包括專門的服裝和療法,這會給患者帶來沉重的經濟負擔,尤其是在公共醫療保險或保險計劃有限的情況下。
  • 透過加強醫學教育、標準化篩檢方案和進行公眾意識宣傳活動來解決這些漏診問題,對於改善患者預後至關重要。區域和地方衛生組織經常強調倡導和教育舉措,以改善早期發現和護理。此外,專用壓力衣、氣動幫浦和手動淋巴引流療法相對較高且持續的費用,對於價格敏感的消費者來說,可能構成持續治療的重大障礙,尤其是在保險覆蓋範圍有限或經濟緊張的亞太地區。該地區終身管理的自付費用仍然很高。
  • 儘管人們的認識正在逐漸提高,但人們認為這種疾病缺乏「治癒方法」以及慢性病的性質仍然會阻礙主動管理,特別是對於那些沒有足夠保險或無法獲得專門護理的人來說。
  • 透過加強對醫療服務提供者和公眾的教育措施、改善保險報銷政策以及開發更實惠、更容易獲得的淋巴水腫管理方案來克服這些挑戰,對於持續的市場成長和改善數百萬淋巴水腫患者的生活品質至關重要

亞太淋巴水腫治療市場範圍

市場根據治療類型、類型、受影響區域、年齡層、給藥途徑、最終用戶和分銷管道進行細分。

按治療類型

根據治療類型,淋巴水腫市場細分為壓迫療法、手術、藥物治療、雷射治療和其他療法。壓迫療法預計將在2025年佔據最大的市場收入份額,達到66.87%,這得益於其作為淋巴水腫治療黃金標準的良好聲譽,以及其非侵入性特性,使其適用於廣泛的患者群體。患者通常優先考慮壓迫療法,因為它能夠有效消腫並提高舒適度。由於材料和設計的不斷進步,舒適度和依從性不斷提高,市場對壓力服和壓力泵的需求也強勁。

預計在預測期內,亞太地區的外科手術領域將迎來最快的增長速度,這得益於淋巴靜脈吻合術 (LVA) 和血管化淋巴結移植術 (VLNT) 等顯微外科技術的不斷進步,以及患者對這些重症病例潛在治癒方案的認識不斷提高。外科手術有望顯著減少長期肢體體積,因此非常適合對保守治療無效的患者。專科淋巴水腫外科中心數量的不斷增加以及對外科手術療效的日益認可,也促進了外科手術的普及。

按類型

根據類型,亞太地區的淋巴水腫治療市場分為原發性淋巴水腫和繼發性淋巴水腫。預計到2025年,繼發性淋巴水腫將佔據最大的市場收入份額,達到78.58%,這主要得益於該地區淋巴水腫的盛行率顯著升高,這主要歸因於淋巴結清除術和放射治療等癌症治療。醫療保健提供者和患者通常優先考慮繼發性淋巴水腫的治療,因為它與挽救生命的癌症幹預措施相關,且發病更容易識別。隨著癌症存活率的提高以及人們對其治療後併發症的認識不斷提高,市場對針對繼發性淋巴水腫的解決方案的需求也十分強勁。

預計原發性淋巴水腫領域將在預測期內實現最快的增長,這得益於人們對這種常伴有遺傳性和早發性疾病的認識和診斷能力的提高,以及基因檢測和兒科淋巴水腫專科護理的進步。對原發性淋巴水腫相關基因突變的深入了解有助於更早診斷。

按受影響區域

根據受影響區域,亞太地區淋巴水腫治療市場可細分為下肢、上肢和生殖器。預計下肢淋巴水腫領域將繼續佔據亞太地區最大的市場收入份額,佔53.28%,這與全球趨勢相符。這主要歸因於亞洲部分地區絲蟲性淋巴水腫的高發生率,以及與慢性靜脈功能不全相關的淋巴水腫病例的增加,以及婦科和前列腺癌發病率的上升。亞太地區患有下肢淋巴水腫的患者通常因嚴重的功能障礙、行動不便和不適而尋求治療,這導致對治療方案的需求持續增長。

預計亞太地區上肢淋巴水腫市場在預測期內將迎來最快的成長,這得益於該地區乳癌倖存者人數的不斷增加。乳癌治療,尤其是腋窩淋巴結清除術和放射治療,仍然是上肢淋巴水腫的主要危險因子。亞太地區腫瘤患者和醫療保健提供者對手臂淋巴水腫篩檢、早期診斷和介入的認識不斷提高,推動了對客製化解決方案的需求。專用上肢臂套和氣動加壓裝置的不斷發展和普及,進一步促進了其市場份額的不斷增長。

按年齡組

亞太地區淋巴水腫治療市場按年齡層細分為成人、老年及兒童。 預計成人市場將繼續佔據亞太地區最大的市場收入份額。這主要是由於與癌症治療相關的繼發性淋巴水腫發生率高,例如乳癌、婦科癌和攝護腺癌的治療。由於生活方式的改變、環境因素以及癌症診斷技術的進步,這些疾病在亞太地區成年人口中日益普遍。此外,各種後天因素,包括創傷、感染(例如某些流行地區的絲蟲病)和其他疾病,都會導致成人淋巴功能障礙。由於亞太地區成人患者群體龐大且對現有治療方案的認識日益加深,因此成為尋求淋巴水腫治療的最大群體。此外,市場還受益於專為成人淋巴水腫管理量身定制的廣泛產品和解決方案。

預計在預測期內,老年醫學領域將見證亞太地區最快的成長速度。這一加速增長的動力源於亞太地區老齡人口的顯著增長,而老齡人口更容易受到與年齡相關的淋巴功能衰退的影響,導致淋巴功能下降。慢性靜脈功能不全、肥胖和其他與年齡相關的慢性疾病等併發症的盛行率不斷上升,也導致老年人淋巴水腫的發生率上升。隨著許多亞太國家預期壽命的持續增長,老年人慢性疾病(包括淋巴水腫)的負擔也不斷加重。

依給藥途徑

根據給藥途徑,亞太淋巴水腫治療市場分為口服、注射和外用。預計到2025年,口服藥物將在亞太地區佔據最大市場份額,達到51.84%。這得益於輔助藥物的便利性,例如用於控制腫脹症狀的利尿劑、用於預防或治療復發性蜂窩性組織炎(淋巴水腫的常見併發症)的抗生素以及各種消炎藥物,均可在家中使用。此外,人們對旨在改善淋巴功能的新興口服療法的興趣和研究也日益增多。亞太地區患者通常更喜歡口服藥物,因為口服藥物易於自行服用,這有助於患者在臨床治療之外更好地遵守治療計劃。

預計注射劑市場將在預測期內成為亞太地區成長最快的領域。這項快速擴張得益於新型生物療法、生長因子(例如刺激淋巴再生的VEGF-C)和基因療法的持續研發。這些先進的治療方法通常需要腸外(注射)給藥,以有效刺激淋巴再生、減輕發炎或調節病情進展。

按最終用戶

根據最終用戶,淋巴水腫治療市場可細分為醫院、專科診所、門診手術中心 (ASC) 和其他類型。預計醫院將佔據最大市場份額。這種優點歸功於醫院能夠提供全方位的淋巴水腫治療方案——從早期保守療法(如手動淋巴引流和壓迫療法)到先進的外科手術(如淋巴靜脈吻合術和帶血管的淋巴結移植)。醫院也是複雜或晚期病例的主要轉診點,這些病例需要多學科護理,包括影像學、診斷和外科幹預。

預計專科診所細分市場將在預測期內實現最快的成長。這一增長主要得益於越來越多專注於淋巴水腫的康復和門診護理中心的出現,這些中心提供非侵入性治療和慢性病管理。這些診所專門服務於需要定期治療的輕度至中度淋巴水腫患者,使其成為經濟實惠且便捷的醫院就診替代方案。日益增加的宣傳活動和政府主導的慢性水腫管理舉措,尤其是在城市地區,進一步推動了專科診所的蓬勃發展。

按分銷管道

根據分銷管道,全球淋巴水腫治療市場可細分為藥局、商店、直接招標和其他管道。預計直接招標管道將佔據市場主導地位。這主要是因為公立醫院、復健中心和政府衛生機構大量採購醫療設備,例如壓力幫浦、防護衣和手術包。直接招標管道確保採購流程精簡、符合監管標準並獲得優惠價格,使其成為大型機構買家的首選。

預計門市細分市場(包括零售和線上通路)將成為預測期內成長最快的細分市場。這種快速擴張歸因於患者行為轉向居家淋巴水腫管理,尤其是在新冠疫情之後。線上購物的便利性、電商滲透率的不斷提升以及壓力袖套和繃帶等自我管理設備的普及,加速了該細分市場的成長。此外,遠距醫療服務的興起使患者能夠在家中管理早期淋巴水腫,從而增加了對非處方藥和電商治療工具的依賴。

亞太淋巴水腫治療市場區域分析

  • 預計亞太地區 (APAC) 淋巴水腫治療市場將出現顯著增長,複合年增長率為 12.8%,這得益於淋巴水腫病例患病率的上升(特別是由於某些地區癌症發病率的上升和持續性淋巴絲蟲病)、醫療保健基礎設施的持續改善以及對醫療進步的投資不斷增加。
  • 該地區的醫療保健提供者和患者越來越認識到現有診斷工具的價值、不斷擴大的治療選擇以及不斷發展的專科診所和醫院所提供的日益增多的意識活動的影響。
  • 可支配收入的增加、多個國家醫療保險滲透率的提高以及對慢性病管理的積極主動態度進一步支持了這種日益增長的採用,逐漸將淋巴水腫護理確立為癌症倖存者和其他淋巴系統疾病患者治療途徑的組成部分。

中國淋巴水腫治療市場洞察

中國淋巴水腫市場正在快速擴張,預計2025年至2032年的複合年增長率將達到14.9%,這得益於與癌症治療相關的繼發性淋巴水腫發病率的不斷上升(例如,婦科腫瘤手術後為20-50%),以及龐大的淋巴絲蟲病現有患者群體。醫療保健專業人員和患者越來越重視透過包括傳統中醫藥療法在內的綜合治療方案對淋巴水腫進行早期發現和有效管理。臨床醫師對淋巴水腫的認識日益加深,加上對專業壓迫療法、氣動幫浦以及血管化淋巴結移植(VLNT)等新型外科技術的強勁需求,進一步推動了淋巴水腫產業的發展。此外,扶持政策與「淋巴水腫關懷行動」等公益計畫的日益融合,以及政府資金的不斷增加和研發的不斷進步,都顯著促進了市場的成長,提高了病患獲得長期照護的管道和依從性。

日本淋巴水腫治療市場洞察

日本淋巴水腫市場正經歷顯著成長,預計2025-2035年的複合年增長率將達到13.33%,這得益於其高發病率(估計約15萬例)以及完善先進的醫療基礎設施。醫護人員和患者越來越重視透過綜合治療方案對淋巴水腫進行早期發現和有效管理,尤其重視完全減充血療法 (CDT) 和淋巴靜脈吻合術 (LVA) 等先進的顯微外科技術。臨床醫師對淋巴水腫的認知度不斷提高,加上對專業壓迫療法、吲哚菁綠螢光淋巴造影等創新診斷工具以及團隊合作式護理的強勁需求,進一步推動了淋巴水腫產業的發展。此外,超顯微外科器械的不斷發展、國際患者的積極接納以及日益增多的宣傳活動,都極大地促進了市場擴張,提高了患者獲得長期護理的管道和依從性。

印度淋巴水腫治療市場洞察

印度淋巴水腫市場預計將大幅成長,這得益於淋巴水腫病例的高發生率,尤其是淋巴絲蟲病造成的沉重負擔(截至 2023 年已報告超過 60 萬例淋巴水腫病例),以及癌症相關淋巴水腫發生率的不斷上升。醫療保健專業人員和患者越來越認識到透過結合常規治療和綜合治療方案來早期發現和有效管理淋巴水腫的重要性。臨床醫生對淋巴水腫的認識不斷提高,加上對負擔得起的壓迫療法的需求不斷增長、醫療器械供應日益充足以及醫療設施不斷擴大,進一步推動了淋巴水腫行業的發展。此外,儘管在認知度和專業培訓方面存在挑戰,但公共衛生計畫為控制絲蟲病所做出的持續努力、醫療保健支出的增加以及對改善城鄉地區醫療服務可及性的日益重視,都極大地促進了市場擴張,提高了患者獲得長期護理的機會和依從性。

亞太淋巴水腫治療市佔率

淋巴水腫治療產業主要由知名公司主導,包括:

  • Tactile Medical(美國)
  • Essity Aktiebolag (publ)(瑞典)
  • 3M(美國)
  • 康德樂(美國)
  • Lohmann & Rauscher GmbH & Co. KG(德國)
  • PAUL HARTMANN AG(德國)
  • medi GmbH & Co. KG(德國)
  • 康維特公司(英國)
  • Juzo(德國)
  • Smith + Nephew(英國)
  • SIGVARIS集團(瑞士)
  • Sanyleg Srl(義大利)
  • Avet Pharmaceuticals Inc.(美國)
  • ThermoTek Inc.(美國)
  • Huntleigh Healthcare Limited(英國)
  • KOYA醫療(美國)
  • AIROS Medical, Inc.(美國)
  • 生物壓縮系統(美國)

亞太淋巴水腫治療市場的最新發展

  • 2025年3月,康維德宣布與傷口、造口和失禁護理師協會 (WOCN) 進行全球合作,以改善造口護理教育。此次合作將啟動兩項免費項目—高級造口護理項目和造口護理助理 (OCA) 項目,為全球超過750名醫療保健專業人員提供培訓。該計畫旨在提高護理標準,並擴大患者獲得專業造口護理的機會。
  • 2025年4月,Lohmann & Rauscher (L&R) 集團收購了英國領先的客製化手術包和外科產品供應商Unisurge International Ltd.。此次策略性收購增強了L&R在英國醫院市場的准入。 Unisurge將獨立運營,保留其領導層和員工,同時受益於L&R的全球專業知識和對醫療創新的承諾。
  • 2025年2月,Tactile Medical 在美國擴大了其 Nimbl 氣動壓縮裝置的上市範圍,用於治療下肢淋巴水腫,此前該裝置最初用於治療上肢疾病。 Nimbl 是同類產品中尺寸最小、支援藍牙的 PCD,其設計注重舒適性、便攜性和更高的依從性。它與 Kylee 應用程式集成,可提升患者體驗和居家自我照護。
  • 2024年10月,Tactile Medical推出了其新一代氣動壓縮裝置Nimbl,用於治療上肢淋巴水腫。 Nimbl已獲得FDA和CMS批准,比之前的型號輕68%,體積縮小40%。它專為家庭使用和日常便利而設計,可與Kylee應用程式集成,增強患者監測。預計下肢版本即將在全國推出。
  • 2022年7月,Tactile Medical為其Flexitouch Plus系統推出了ComfortEase系列服裝,該系列服裝經過重新設計,更加貼合、舒適且易於使用。此外,該公司還推出了Kylee行動應用程序,幫助患者追蹤淋巴水腫症狀、記錄治療過程並獲取相關教育資源。這兩項創新旨在提高居家治療的依從性,並提高患者在管理慢性腫脹疾病方面的參與度。


SKU-

Get online access to the report on the World's First Market Intelligence Cloud

  • Interactive Data Analysis Dashboard
  • Company Analysis Dashboard for high growth potential opportunities
  • Research Analyst Access for customization & queries
  • Competitor Analysis with Interactive dashboard
  • Latest News, Updates & Trend analysis
  • Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
Request for Demo

目录

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF ASIA-PACIFIC LYMPHEDEMA TREATMENT MARKET

1.4 LIMITATIONS

1.5 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 CURRENCY AND PRICING

2.5 DBMR TRIPOD DATA VALIDATION MODEL

2.6 MULTIVARIATE MODELLING

2.7 PRODUCT TYPE LIFELINE CURVE

2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.9 DBMR MARKET POSITION GRID

2.1 MARKET END USER COVERAGE GRID

2.11 VENDOR SHARE ANALYSIS

2.12 SECONDARY SOURCES

2.13 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 PORTER’S FIVE FORCES

4.2 PESTEL ANALYSIS

4.3 INDUSTRY INSIGHTS –

4.3.1 MICRO AND MACROECONOMIC FACTORS

4.3.2 PENETRATION AND GROWTH PROSPECT MAPPING

4.3.3 KEY PRICING STRATEGIES

4.3.4 ANALYSIS AND RECOMMENDATION

4.4 INNOVATION TRACKER & STRATEGIC ANALYSIS

4.4.1 MAJOR DEALS AND STRATEGIC ALLIANCES ANALYSIS

4.4.1.1 MERGERS & ACQUISITIONS

4.4.1.2 TECHNOLOGY COLLABORATIONS

4.4.2 NUMBER OF PRODUCTS IN DEVELOPMENT

4.4.3 STAGE OF DEVELOPMENT

4.4.4 TIMELINES & MILESTONES

4.4.5 INNOVATION STRATEGIES & METHODOLOGIES

4.4.6 RISK ASSESSMENT & MITIGATION

4.4.7 FUTURE OUTLOOK

4.5 PIPELINE ANALYSIS – ASIA-PACIFIC LYMPHEDEMA TREATMENT MARKET

4.5.1 CLINICAL TRIALS AND PHASE ANALYSIS

4.5.2 DRUG THERAPY PIPELINE

4.5.3 PHASE III CANDIDATES

4.5.4 PHASE II CANDIDATES

4.5.5 PHASE I CANDIDATES

4.5.6 OTHERS (PRE-CLINICAL AND RESEARCH)

4.5.7 CONCLUSION

4.6 EPIDEMIOLOGY–

4.6.1 INCIDENCE OF LYMPHEDEMA (ASIA-PACIFIC & BY GENDER)

4.6.2 INCIDENCE OF LYMPHEDEMA BY GENDER

4.6.3 TREATMENT RATE

4.6.4 MORTALITY RATE

4.6.5 DRUG ADHERENCE AND THERAPY SWITCH MODEL

4.6.6 PATIENT TREATMENT SUCCESS RATES

4.7 TARIFF

4.7.1 OVERVIEW

4.7.2 TARIFF STRUCTURES

4.7.2.1 Asia-Pacific vs. Regional Tariff Structures

4.7.2.2 United States: Medicare/Medicaid Tariff Policies, CMS Pricing Models

4.7.2.3 European Union: Cross-border Tariff Regulations and Reimbursement Policies

4.7.2.4 Asia-Pacific: Government-imposed Tariffs on Imported Medical Products

4.7.2.5 Emerging Markets: Challenges in Tariff Implementation

4.7.3 PHARMACEUTICAL TARIFFS AND TRADE BARRIERS

4.7.3.1 Import Duties on Prescription Drugs vs. Generics

4.7.3.2 Impact on Drug Affordability and Access

4.7.3.3 Key Trade Agreements Affecting Pharmaceutical Tariffs

4.7.4 IMPACT OF HEALTHCARE TARIFFS ON PROVIDERS AND PATIENTS

4.7.4.1 Cost Burden on Hospitals and Healthcare Facilities

4.7.4.2 Effect on Patient Affordability and Insurance Coverage

4.7.4.3 Tariffs and Their Role in Medical Tourism

4.7.5 TRADE AGREEMENTS AND HEALTHCARE TARIFFS

4.7.5.1 WTO Regulations on Healthcare Tariffs

4.7.5.2 Impact of Trade Wars on the Healthcare Supply Chain

4.7.5.3 Role of Free Trade Agreements (FTAs) in Reducing Tariffs

4.7.6 IMPACT OF TARIFFS ON HEALTHCARE COSTS AND ACCESSIBILITY

4.7.7 IMPORTANCE OF TARIFFS IN THE HEALTHCARE SECTOR

5 REGULATORY FRAMEWORK–

5.1 NORTH AMERICA

5.2 SOUTH AMERICA

5.3 EUROPE

5.4 ASIA-PACIFIC

5.5 MIDDLE EAST & AFRICA

6 MARKET OVERVIEW

6.1 DRIVERS

6.1.1 RISE IN THE NUMBER OF LYMPHEDEMA CASES GLOBALLY

6.1.2 INCREASE IN THE PREVALENCE OF CANCERS

6.1.3 INCREASING NUMBER OF HEALTHCARE FACILITIES

6.1.4 AVAILABILITY AND ADVANCEMENT OF MULTIPLE THERAPEUTIC OPTIONS

6.2 RESTRAINTS

6.2.1 SIGNIFICANT COST BURDEN ASSOCIATED WITH LYMPHEDEMA MANAGEMENT

6.2.2 LACK OF AWARENESS ABOUT THE DISEASE

6.3 OPPORTUNITIES

6.3.1 EXPANDING OPPORTUNITIES FOR DRUG DEVELOPMENT AND REGULATORY APPROVALS

6.3.2 STRATEGIC COLLABORATIONS AND ALLIANCES AMONG INDUSTRY STAKEHOLDERS

6.4 CHALLENGES

6.4.1 ABSENCE OF A DEFINITIVE CURATIVE TREATMENT

6.4.2 RESTRICTIVE AND INCONSISTENT REIMBURSEMENT POLICIES

7 ASIA-PACIFIC LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE

7.1 OVERVIEW

7.2 COMPRESSION THERAPY

7.3 SURGERY

7.4 DRUG THERAPY

7.5 LASER THERAPY

7.6 OTHERS

8 ASIA-PACIFIC LYMPHEDEMA TREATMENT MARKET, BY TYPE

8.1 OVERVIEW

8.2 SECONDARY LYMPHEDEMA

8.3 PRIMARY LYMPHEDEMA

9 ASIA-PACIFIC LYMPHEDEMA TREATMENT MARKET, BY AFFECTED AREA

9.1 OVERVIEW

9.2 LOWER EXTREMITY

9.3 UPPER EXTREMITY

9.4 GENITALIA

10 ASIA-PACIFIC LYMPHEDEMA TREATMENT MARKET, BY AGE GROUP

10.1 OVERVIEW

10.2 ADULT

10.3 GERIATRIC

10.4 PEDIATRIC

11 ASIA-PACIFIC LYMPHEDEMA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION

11.1 OVERVIEW

11.2 ORAL

11.3 INJECTABLE

11.4 TOPICAL

12 ASIA-PACIFIC LYMPHEDEMA TREATMENT MARKET, BY END USER

12.1 OVERVIEW

12.2 HOSPITAL

12.3 SPECIALTY CLINICS

12.4 AMBULATORY SURGICAL CENTERS

12.5 OTHERS

13 ASIA-PACIFIC LYMPHEDEMA TREATMENT MARKET, BY DISTRIBUTION CHANNEL

13.1 OVERVIEW

13.2 PHARMACY STORES

13.3 DIRECT TENDER

13.4 OTHERS

14 ASIA-PACIFIC LYMPHEDEMA TREATMENT MARKET, BY REGION

14.1 ASIA-PACIFIC

14.1.1 CHINA

14.1.2 JAPAN

14.1.3 INDIA

14.1.4 SOUTH KOREA

14.1.5 AUSTRALIA

14.1.6 INDONESIA

14.1.7 SINGAPORE

14.1.8 PHILIPPINES

14.1.9 THAILAND

14.1.10 MALAYSIA

14.1.11 VIETNAM

14.1.12 REST OF ASIA-PACIFIC

15 ASIA-PACIFIC LYMPHEDEMA TREATMENT MARKET, COMPANY LANDSCAPE

15.1 COMPANY SHARE ANALYSIS: ASIA-PACIFIC

16 SWOT ANALYSIS

17 COMPANY PROFILE

17.1 TACTILE MEDICAL

17.1.1 COMPANY SNAPSHOT

17.1.2 REVENUE ANALYSIS

17.1.3 COMPANY SHARE ANALYSIS

17.1.4 PRODUCT PORTFOLIO

17.1.5 RECENT DEVELOPMENT

17.2 ESSITY AKTIEBOLAG (PUBL)

17.2.1 COMPANY SNAPSHOT

17.2.2 REVENUE ANALYSIS

17.2.3 COMPANY SHARE ANALYSIS

17.2.4 PRODUCT PORTFOLIO

17.2.5 RECENT DEVELOPMENT

17.3 3M

17.3.1 COMPANY SNAPSHOT

17.3.2 REVENUE ANALYSIS

17.3.3 COMPANY SHARE ANALYSIS

17.3.4 PRODUCT PORTFOLIO

17.3.5 RECENT DEVELOPMENTS

17.4 CARDINAL HEALTH

17.4.1 COMPANY SNAPSHOT

17.4.2 REVENUE ANALYSIS

17.4.3 COMPANY SHARE ANALYSIS

17.4.4 PRODUCT PORTFOLIO

17.4.5 RECENT DEVELOPMENT

17.5 LOHMANN & RAUSCHER GMBH & CO. KG

17.5.1 COMPANY SNAPSHOT

17.5.2 COMPANY SHARE ANALYSIS

17.5.3 PRODUCT PORTFOLIO

17.5.4 RECENT DEVELOPMENT

17.6 AIROS MEDICAL, INC.

17.6.1 COMPANY SNAPSHOT

17.6.2 PRODUCT PORTFOLIO

17.6.3 RECENT DEVELOPMENT

17.7 ARJO

17.7.1 COMPANY SNAPSHOT

17.7.2 REVENUE ANALYSIS

17.7.3 PRODUCT PORTFOLIO

17.7.4 RECENT DEVELOPMENTS

17.8 AVET PHARMACEUTICALS INC.

17.8.1 COMPANY SNAPSHOT

17.8.2 PRODUCT PORTFOLIO

17.8.3 RECENT DEVELOPMENT

17.9 BAUERFEIND

17.9.1 COMPANY SNAPSHOT

17.9.2 PRODUCT PORTFOLIO

17.9.3 RECENT DEVELOPMENTS

17.1 BIOCOMPRESSION SYSTEMS

17.10.1 COMPANY SNAPSHOT

17.10.2 PRODUCT PORTFOLIO

17.10.3 RECENT DEVELOPMENT

17.11 CONVATEC INC.

17.11.1 COMPANY SNAPSHOT

17.11.2 PRODUCT PORTFOLIO

17.11.3 RECENT DEVELOPMENT

17.12 ENOVIS CORPORATION

17.12.1 COMPANY SNAPSHOT

17.12.2 REVENUE ANALYSIS

17.12.3 PRODUCT PORTFOLIO

17.12.4 RECENT DEVELOPMENTS

17.13 HUNTLEIGH HEALTHCARE LIMITED

17.13.1 COMPANY SNAPSHOT

17.13.2 PRODUCT PORTFOLIO

17.13.3 RECENT DEVELOPMENT

17.14 IMPEDIMED LIMITED

17.14.1 COMPANY SNAPSHOT

17.14.2 REVENUE ANALYSIS

17.14.3 PRODUCT PORTFOLIO

17.14.4 RECENT DEVELOPMENT/NEWS

17.15 JODAS EXPOIM PVT. LTD.

17.15.1 COMPANY SNAPSHOT

17.15.2 PRODUCT PORTFOLIO

17.15.3 RECENT DEVELOPMENT

17.16 JUZO

17.16.1 COMPANY SNAPSHOT

17.16.2 PRODUCT PORTFOLIO

17.16.3 RECENT DEVELOPMENT

17.17 KOYA MEDICAL

17.17.1 COMPANY SNAPSHOT

17.17.2 PRODUCT PORTFOLIO

17.17.3 RECENT DEVELOPMENT

17.18 LLC BINNOPHARM GROUP

17.18.1 COMPANY SNAPSHOT

17.18.2 PRODUCT PORTFOLIO

17.18.3 RECENT DEVELOPMENT

17.19 MCKESSON MEDICAL-SURGICAL INC.

17.19.1 COMPANY SNAPSHOT

17.19.2 REVENUE ANALYSIS

17.19.3 PRODUCT PORTFOLIO

17.19.4 RECENT DEVELOPMENT

17.2 MEDI GMBH & CO. KG

17.20.1 COMPANY SNAPSHOT

17.20.2 PRODUCT PORTFOLIO

17.20.3 RECENT DEVELOPMENT

17.21 MEDTRONIC

17.21.1 COMPANY SNAPSHOT

17.21.2 REVENUE ANALYSIS

17.21.3 PRODUCT PORTFOLIO

17.21.4 RECENT DEVELOPMENTS

17.22 MEGO AFEK LTD

17.22.1 COMPANY SNAPSHOT

17.22.2 PRODUCT PORTFOLIO

17.22.3 RECENT DEVELOPMENT

17.23 PAUL HARTMANN AG

17.23.1 COMPANY SNAPSHOT

17.23.2 REVENUE ANALYSIS

17.23.3 PRODUCT PORTFOLIO

17.23.4 RECENT DEVELOPMENT

17.24 PERFORMANCE HEALTH

17.24.1 COMPANY SNAPSHOT

17.24.2 PRODUCT PORTFOLIO

17.24.3 RECENT DEVELOPMENTS

17.25 PURETECH HEALTH INC

17.25.1 COMPANY SNAPSHOT

17.25.2 PIPELINE PORTFOLIO

17.25.3 RECENT DEVELOPMENT

17.26 SANYLEG SRL A SOCIO UNICO

17.26.1 COMPANY SNAPSHOT

17.26.2 PRODUCT PORTFOLIO

17.26.3 RECENT DEVELOPMENT

17.27 SIGVARIS GROUP

17.27.1 COMPANY SNAPSHOT

17.27.2 PRODUCT PORTFOLIO

17.27.3 RECENT DEVELOPMENTS

17.28 SMITH+NEPHEW

17.28.1 COMPANY SNAPSHOT

17.28.2 REVENUE ANALYSIS

17.28.3 PRODUCT PORTFOLIO

17.28.4 RECENT DEVELOPMENT

17.29 THERMOTEK

17.29.1 COMPANY SNAPSHOT

17.29.2 PRODUCT PORTFOLIO

17.29.3 RECENT DEVELOPMENT

17.3 THUASNE

17.30.1 COMPANY SNAPSHOT

17.30.2 PRODUCT PORTFOLIO

17.30.3 RECENT DEVELOPMENT

17.31 VIATRIS INC.

17.31.1 COMPANY SNAPSHOT

17.31.2 REVENUE ANALYSIS

17.31.3 PRODUCT PORTFOLIO

17.31.4 RECENT DEVELOPMENT

17.32 WHITE SWAN PHARMACEUTICAL

17.32.1 COMPANY SNAPSHOT

17.32.2 PRODUCT PORTFOLIO

17.32.3 RECENT DEVELOPMENTS

18 QUESTIONNAIRE

19 RELATED REPORTS

表格列表

TABLE 1  PRODUCTS AND THEIR STAGES IN DEVELOPMENT.

TABLE 2  PHASE-WISE DISTRIBUTION: CLINICAL TRIALS

TABLE 3  PHASE 2 CANDIDATES

TABLE 4  ASIA-PACIFIC LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 5  ASIA-PACIFIC LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 6  ASIA-PACIFIC COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY REGION 2018-2032 (USD THOUSAND)

TABLE 7  ASIA-PACIFIC COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2018-2032 (USD THOUSAND)

TABLE 8  ASIA-PACIFIC COMPRESSION GARMENTS IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2018-2032 (USD THOUSAND)

TABLE 9  ASIA-PACIFIC COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TECHNIQUE, 2018-2032 (USD THOUSAND)

TABLE 10  ASIA-PACIFIC SURGERY IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 11  ASIA-PACIFIC SURGERY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 12  ASIA-PACIFIC DRUG THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 13  ASIA-PACIFIC DRUG THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 14  ASIA-PACIFIC LASER THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 15  ASIA-PACIFIC OTHERS IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 16  ASIA-PACIFIC LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 17  ASIA-PACIFIC SECONDARY LYMPHEDEMA IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 18  ASIA-PACIFIC PRIMARY LYMPHEDEMA IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 19  ASIA-PACIFIC PRIMARY LYMPHEDEMA IN LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 20  ASIA-PACIFIC LYMPHEDEMA TREATMENT MARKET, BY AFFECTED AREA, 2018-2032 (USD THOUSAND)

TABLE 21  ASIA-PACIFIC LOWER EXTREMITY IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 22  ASIA-PACIFIC UPPER EXTREMITY IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 23  ASIA-PACIFIC GENITALIA IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 24  ASIA-PACIFIC LYMPHEDEMA TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)

TABLE 25  ASIA-PACIFIC ADULT IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 26  ASIA-PACIFIC GERIATRIC IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 27  ASIA-PACIFIC PEDIATRIC IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 28  ASIA-PACIFIC LYMPHEDEMA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)

TABLE 29  ASIA-PACIFIC ORAL IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 30  ASIA-PACIFIC INJECTABLE IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 31  ASIA-PACIFIC TOPICAL IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 32  ASIA-PACIFIC LYMPHEDEMA TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 33  ASIA-PACIFIC HOSPITAL IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 34  ASIA-PACIFIC SPECIALITY CLINICS IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 35  ASIA-PACIFIC AMBULATORY SURGICAL CENTERS IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 36  ASIA-PACIFIC OTHERS IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 37  ASIA-PACIFIC LYMPHEDEMA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 38  ASIA-PACIFIC PHARMACY STORES IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 39  ASIA-PACIFIC DIRECT TENDER IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 40  ASIA-PACIFIC OTHERS IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 41  ASIA-PACIFIC LYMPHEDEMA TREATMENT MARKET, BY COUNTRY, 2018-2032 (USD THOUSAND)

TABLE 42  ASIA-PACIFIC LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 43  ASIA-PACIFIC LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 44  ASIA-PACIFIC LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 45  ASIA-PACIFIC COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2018-2032 (USD THOUSAND)

TABLE 46  ASIA-PACIFIC COMPRESSION GARMENTS IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2018-2032 (USD THOUSAND)

TABLE 47  ASIA-PACIFIC COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TECHNIQUE, 2018-2032 (USD THOUSAND)

TABLE 48  ASIA-PACIFIC SURGERY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 49  ASIA-PACIFIC DRUG THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 50  ASIA-PACIFIC LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 51  ASIA-PACIFIC PRIMARY LYMPHEDEMA IN LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 52  ASIA-PACIFIC LYMPHEDEMA TREATMENT MARKET, BY AFFECTED AREA, 2018-2032 (USD THOUSAND)

TABLE 53  ASIA-PACIFIC LYMPHEDEMA TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)

TABLE 54  ASIA-PACIFIC LYMPHEDEMA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)

TABLE 55  ASIA-PACIFIC LYMPHEDEMA TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 56  ASIA-PACIFIC LYMPHEDEMA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 57  CHINA LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 58  CHINA LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 59  CHINA LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 60  CHINA COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2018-2032 (USD THOUSAND)

TABLE 61  CHINA COMPRESSION GARMENTS IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2018-2032 (USD THOUSAND)

TABLE 62  CHINA COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TECHNIQUE, 2018-2032 (USD THOUSAND)

TABLE 63  CHINA SURGERY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 64  CHINA DRUG THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 65  CHINA LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 66  CHINA PRIMARY LYMPHEDEMA IN LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 67  CHINA LYMPHEDEMA TREATMENT MARKET, BY AFFECTED AREA, 2018-2032 (USD THOUSAND)

TABLE 68  CHINA LYMPHEDEMA TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)

TABLE 69  CHINA LYMPHEDEMA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)

TABLE 70  CHINA LYMPHEDEMA TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 71  CHINA LYMPHEDEMA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 72  JAPAN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 73  JAPAN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 74  JAPAN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 75  JAPAN COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2018-2032 (USD THOUSAND)

TABLE 76  JAPAN COMPRESSION GARMENTS IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2018-2032 (USD THOUSAND)

TABLE 77  JAPAN COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TECHNIQUE, 2018-2032 (USD THOUSAND)

TABLE 78  JAPAN SURGERY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 79  JAPAN DRUG THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 80  JAPAN LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 81  JAPAN PRIMARY LYMPHEDEMA IN LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 82  JAPAN LYMPHEDEMA TREATMENT MARKET, BY AFFECTED AREA, 2018-2032 (USD THOUSAND)

TABLE 83  JAPAN LYMPHEDEMA TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)

TABLE 84  JAPAN LYMPHEDEMA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)

TABLE 85  JAPAN LYMPHEDEMA TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 86  JAPAN LYMPHEDEMA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 87  INDIA LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 88  INDIA LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 89  INDIA LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 90  INDIA COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2018-2032 (USD THOUSAND)

TABLE 91  INDIA COMPRESSION GARMENTS IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2018-2032 (USD THOUSAND)

TABLE 92  INDIA COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TECHNIQUE, 2018-2032 (USD THOUSAND)

TABLE 93  INDIA SURGERY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 94  INDIA DRUG THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 95  INDIA LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 96  INDIA PRIMARY LYMPHEDEMA IN LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 97  INDIA LYMPHEDEMA TREATMENT MARKET, BY AFFECTED AREA, 2018-2032 (USD THOUSAND)

TABLE 98  INDIA LYMPHEDEMA TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)

TABLE 99  INDIA LYMPHEDEMA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)

TABLE 100  INDIA LYMPHEDEMA TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 101  INDIA LYMPHEDEMA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 102  SOUTH KOREA LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 103  SOUTH KOREA LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 104  SOUTH KOREA LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 105  SOUTH KOREA COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2018-2032 (USD THOUSAND)

TABLE 106  SOUTH KOREA COMPRESSION GARMENTS IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2018-2032 (USD THOUSAND)

TABLE 107  SOUTH KOREA COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TECHNIQUE, 2018-2032 (USD THOUSAND)

TABLE 108  SOUTH KOREA SURGERY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 109  SOUTH KOREA DRUG THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 110  SOUTH KOREA LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 111  SOUTH KOREA PRIMARY LYMPHEDEMA IN LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 112  SOUTH KOREA LYMPHEDEMA TREATMENT MARKET, BY AFFECTED AREA, 2018-2032 (USD THOUSAND)

TABLE 113  SOUTH KOREA LYMPHEDEMA TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)

TABLE 114  SOUTH KOREA LYMPHEDEMA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)

TABLE 115  SOUTH KOREA LYMPHEDEMA TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 116  SOUTH KOREA LYMPHEDEMA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 117  AUSTRALIA LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 118  AUSTRALIA LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 119  AUSTRALIA LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 120  AUSTRALIA COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2018-2032 (USD THOUSAND)

TABLE 121  AUSTRALIA COMPRESSION GARMENTS IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2018-2032 (USD THOUSAND)

TABLE 122  AUSTRALIA COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TECHNIQUE, 2018-2032 (USD THOUSAND)

TABLE 123  AUSTRALIA SURGERY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 124  AUSTRALIA DRUG THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 125  AUSTRALIA LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 126  AUSTRALIA PRIMARY LYMPHEDEMA IN LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 127  AUSTRALIA LYMPHEDEMA TREATMENT MARKET, BY AFFECTED AREA, 2018-2032 (USD THOUSAND)

TABLE 128  AUSTRALIA LYMPHEDEMA TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)

TABLE 129  AUSTRALIA LYMPHEDEMA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)

TABLE 130  AUSTRALIA LYMPHEDEMA TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 131  AUSTRALIA LYMPHEDEMA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 132  INDONESIA LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 133  INDONESIA LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 134  INDONESIA LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 135  INDONESIA COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2018-2032 (USD THOUSAND)

TABLE 136  INDONESIA COMPRESSION GARMENTS IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2018-2032 (USD THOUSAND)

TABLE 137  INDONESIA COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TECHNIQUE, 2018-2032 (USD THOUSAND)

TABLE 138  INDONESIA SURGERY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 139  INDONESIA DRUG THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 140  INDONESIA LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 141  INDONESIA PRIMARY LYMPHEDEMA IN LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 142  INDONESIA LYMPHEDEMA TREATMENT MARKET, BY AFFECTED AREA, 2018-2032 (USD THOUSAND)

TABLE 143  INDONESIA LYMPHEDEMA TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)

TABLE 144  INDONESIA LYMPHEDEMA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)

TABLE 145  INDONESIA LYMPHEDEMA TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 146  INDONESIA LYMPHEDEMA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 147  SINGAPORE LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 148  SINGAPORE LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 149  SINGAPORE LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 150  SINGAPORE COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2018-2032 (USD THOUSAND)

TABLE 151  SINGAPORE COMPRESSION GARMENTS IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2018-2032 (USD THOUSAND)

TABLE 152  SINGAPORE COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TECHNIQUE, 2018-2032 (USD THOUSAND)

TABLE 153  SINGAPORE SURGERY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 154  SINGAPORE DRUG THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 155  SINGAPORE LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 156  SINGAPORE PRIMARY LYMPHEDEMA IN LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 157  SINGAPORE LYMPHEDEMA TREATMENT MARKET, BY AFFECTED AREA, 2018-2032 (USD THOUSAND)

TABLE 158  SINGAPORE LYMPHEDEMA TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)

TABLE 159  SINGAPORE LYMPHEDEMA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)

TABLE 160  SINGAPORE LYMPHEDEMA TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 161  SINGAPORE LYMPHEDEMA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 162  PHILIPPINES LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 163  PHILIPPINES LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 164  PHILIPPINES LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 165  PHILIPPINES COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2018-2032 (USD THOUSAND)

TABLE 166  PHILIPPINES COMPRESSION GARMENTS IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2018-2032 (USD THOUSAND)

TABLE 167  PHILIPPINES COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TECHNIQUE, 2018-2032 (USD THOUSAND)

TABLE 168  PHILIPPINES SURGERY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 169  PHILIPPINES DRUG THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 170  PHILIPPINES LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 171  PHILIPPINES PRIMARY LYMPHEDEMA IN LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 172  PHILIPPINES LYMPHEDEMA TREATMENT MARKET, BY AFFECTED AREA, 2018-2032 (USD THOUSAND)

TABLE 173  PHILIPPINES LYMPHEDEMA TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)

TABLE 174  PHILIPPINES LYMPHEDEMA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)

TABLE 175  PHILIPPINES LYMPHEDEMA TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 176  PHILIPPINES LYMPHEDEMA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 177  THAILAND LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 178  THAILAND LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 179  THAILAND LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 180  THAILAND COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2018-2032 (USD THOUSAND)

TABLE 181  THAILAND COMPRESSION GARMENTS IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2018-2032 (USD THOUSAND)

TABLE 182  THAILAND COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TECHNIQUE, 2018-2032 (USD THOUSAND)

TABLE 183  THAILAND SURGERY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 184  THAILAND DRUG THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 185  THAILAND LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 186  THAILAND PRIMARY LYMPHEDEMA IN LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 187  THAILAND LYMPHEDEMA TREATMENT MARKET, BY AFFECTED AREA, 2018-2032 (USD THOUSAND)

TABLE 188  THAILAND LYMPHEDEMA TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)

TABLE 189  THAILAND LYMPHEDEMA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)

TABLE 190  THAILAND LYMPHEDEMA TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 191  THAILAND LYMPHEDEMA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 192  MALAYSIA LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 193  MALAYSIA LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 194  MALAYSIA LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 195  MALAYSIA COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2018-2032 (USD THOUSAND)

TABLE 196  MALAYSIA COMPRESSION GARMENTS IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2018-2032 (USD THOUSAND)

TABLE 197  MALAYSIA COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TECHNIQUE, 2018-2032 (USD THOUSAND)

TABLE 198  MALAYSIA SURGERY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 199  MALAYSIA DRUG THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 200  MALAYSIA LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 201  MALAYSIA PRIMARY LYMPHEDEMA IN LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 202  MALAYSIA LYMPHEDEMA TREATMENT MARKET, BY AFFECTED AREA, 2018-2032 (USD THOUSAND)

TABLE 203  MALAYSIA LYMPHEDEMA TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)

TABLE 204  MALAYSIA LYMPHEDEMA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)

TABLE 205  MALAYSIA LYMPHEDEMA TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 206  MALAYSIA LYMPHEDEMA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 207  VIETNAM LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 208  VIETNAM LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 209  VIETNAM LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 210  VIETNAM COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2018-2032 (USD THOUSAND)

TABLE 211  VIETNAM COMPRESSION GARMENTS IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2018-2032 (USD THOUSAND)

TABLE 212  VIETNAM COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TECHNIQUE, 2018-2032 (USD THOUSAND)

TABLE 213  VIETNAM SURGERY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 214  VIETNAM DRUG THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 215  VIETNAM LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 216  VIETNAM PRIMARY LYMPHEDEMA IN LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 217  VIETNAM LYMPHEDEMA TREATMENT MARKET, BY AFFECTED AREA, 2018-2032 (USD THOUSAND)

TABLE 218  VIETNAM LYMPHEDEMA TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)

TABLE 219  VIETNAM LYMPHEDEMA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)

TABLE 220  VIETNAM LYMPHEDEMA TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 221  VIETNAM LYMPHEDEMA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 222  REST OF ASIA-PACIFIC LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 223  REST OF ASIA-PACIFIC LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 224  REST OF ASIA-PACIFIC LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (ASP IN USD/UNITS)

图片列表

FIGURE 1  ASIA-PACIFIC LYMPHEDEMA TREATMENT MARKET: SEGMENTATION

FIGURE 2  ASIA-PACIFIC LYMPHEDEMA TREATMENT MARKET: DATA TRIANGULATION

FIGURE 3  ASIA-PACIFIC LYMPHEDEMA TREATMENT MARKET: DROC ANALYSIS

FIGURE 4  ASIA-PACIFIC LYMPHEDEMA TREATMENT MARKET: ASIA-PACIFIC VS REGIONAL ANALYSIS

FIGURE 5  ASIA-PACIFIC LYMPHEDEMA TREATMENT MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6  ASIA-PACIFIC LYMPHEDEMA TREATMENT MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7  ASIA-PACIFIC LYMPHEDEMA TREATMENT MARKET: DBMR MARKET POSITION GRID

FIGURE 8  ASIA-PACIFIC LYMPHEDEMA TREATMENT MARKET: MARKET END USER COVERAGE GRID

FIGURE 9  ASIA-PACIFIC LYMPHEDEMA TREATMENT MARKET: VENDOR SHARE ANALYSIS

FIGURE 10  EXECUTIVE SUMMARY

FIGURE 11  FIVE SEGMENTS COMPRISE THE ASIA-PACIFIC LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE (2024)

FIGURE 12  STRATEGIC DECISIONS

FIGURE 13  ASIA-PACIFIC LYMPHEDEMA TREATMENT MARKET: SEGMENTATION

FIGURE 14  INCREASE IN THE PREVALENCE OF CANCERS IS EXPECTED TO DRIVE THE ASIA-PACIFIC LYMPHEDEMA TREATMENT MARKET IN THE FORECAST PERIOD OF 2025 TO 2032

FIGURE 15  THE COMPRESSION THERAPY SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE ASIA-PACIFIC LYMPHEDEMA TREATMENT MARKET IN 2025 AND 2032

FIGURE 16  DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF INDONESIA ZEOLITE MARKET

FIGURE 17  ASIA-PACIFIC LYMPHEDEMA TREATMENT MARKET: BY TREATMENT TYPE, 2024

FIGURE 18  ASIA-PACIFIC LYMPHEDEMA TREATMENT MARKET: BY TREATMENT TYPE, 2025-2032 (USD THOUSAND)

FIGURE 19  ASIA-PACIFIC LYMPHEDEMA TREATMENT MARKET: BY TREATMENT TYPE, CAGR (2025-2032)

FIGURE 20  ASIA-PACIFIC LYMPHEDEMA TREATMENT MARKET: BY TREATMENT TYPE, LIFELINE CURVE

FIGURE 21  ASIA-PACIFIC LYMPHEDEMA TREATMENT MARKET: BY TYPE, 2024

FIGURE 22  ASIA-PACIFIC LYMPHEDEMA TREATMENT MARKET: BY TYPE, 2025-2032 (USD THOUSAND)

FIGURE 23  ASIA-PACIFIC LYMPHEDEMA TREATMENT MARKET: BY TYPE, CAGR (2025-2032)

FIGURE 24  ASIA-PACIFIC LYMPHEDEMA TREATMENT MARKET: BY TYPE, LIFELINE CURVE

FIGURE 25  ASIA-PACIFIC LYMPHEDEMA TREATMENT MARKET: BY AFFECTED AREA, 2024

FIGURE 26  ASIA-PACIFIC LYMPHEDEMA TREATMENT MARKET: BY AFFECTED AREA, 2025-2032 (USD THOUSAND)

FIGURE 27  ASIA-PACIFIC LYMPHEDEMA TREATMENT MARKET: BY AFFECTED AREA, CAGR (2025-2032)

FIGURE 28  ASIA-PACIFIC LYMPHEDEMA TREATMENT MARKET: BY AFFECTED AREA, LIFELINE CURVE

FIGURE 29  ASIA-PACIFIC LYMPHEDEMA TREATMENT MARKET: BY AGE GROUP, 2024

FIGURE 30  ASIA-PACIFIC LYMPHEDEMA TREATMENT MARKET: BY AGE GROUP, 2025-2032 (USD THOUSAND)

FIGURE 31  ASIA-PACIFIC LYMPHEDEMA TREATMENT MARKET: BY AGE GROUP, CAGR (2025-2032)

FIGURE 32  ASIA-PACIFIC LYMPHEDEMA TREATMENT MARKET: BY AGE GROUP, LIFELINE CURVE

FIGURE 33  ASIA-PACIFIC LYMPHEDEMA TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2024

FIGURE 34  ASIA-PACIFIC LYMPHEDEMA TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2025-2032 (USD THOUSAND)

FIGURE 35  ASIA-PACIFIC LYMPHEDEMA TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2025-2032)

FIGURE 36  ASIA-PACIFIC LYMPHEDEMA TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE

FIGURE 37  ASIA-PACIFIC LYMPHEDEMA TREATMENT MARKET: BY END USER, 2024

FIGURE 38  ASIA-PACIFIC LYMPHEDEMA TREATMENT MARKET: BY END USER, 2025-2032 (USD THOUSAND)

FIGURE 39  ASIA-PACIFIC LYMPHEDEMA TREATMENT MARKET: BY END USER, CAGR (2025-2032)

FIGURE 40  ASIA-PACIFIC LYMPHEDEMA TREATMENT MARKET: BY END USER, LIFELINE CURVE

FIGURE 41  ASIA-PACIFIC LYMPHEDEMA TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2024

FIGURE 42  ASIA-PACIFIC LYMPHEDEMA TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2025-2032 (USD THOUSAND)

FIGURE 43  ASIA-PACIFIC LYMPHEDEMA TREATMENT MARKET: BY DISTRIBUTION CHANNEL, CAGR (2025-2032)

FIGURE 44  ASIA-PACIFIC LYMPHEDEMA TREATMENT MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 45  ASIA-PACIFIC LYMPHEDEMA TREATMENT MARKET: SNAPSHOT (2024)

FIGURE 46  ASIA-PACIFIC LYMPHEDEMA TREATMENT MARKET: COMPANY SHARE 2024 (%)

查看详细信息 Right Arrow

研究方法

数据收集和基准年分析是使用具有大样本量的数据收集模块完成的。该阶段包括通过各种来源和策略获取市场信息或相关数据。它包括提前检查和规划从过去获得的所有数据。它同样包括检查不同信息源中出现的信息不一致。使用市场统计和连贯模型分析和估计市场数据。此外,市场份额分析和关键趋势分析是市场报告中的主要成功因素。要了解更多信息,请请求分析师致电或下拉您的询问。

DBMR 研究团队使用的关键研究方法是数据三角测量,其中包括数据挖掘、数据变量对市场影响的分析和主要(行业专家)验证。数据模型包括供应商定位网格、市场时间线分析、市场概览和指南、公司定位网格、专利分析、定价分析、公司市场份额分析、测量标准、全球与区域和供应商份额分析。要了解有关研究方法的更多信息,请向我们的行业专家咨询。

可定制

Data Bridge Market Research 是高级形成性研究领域的领导者。我们为向现有和新客户提供符合其目标的数据和分析而感到自豪。报告可定制,包括目标品牌的价格趋势分析、了解其他国家的市场(索取国家列表)、临床试验结果数据、文献综述、翻新市场和产品基础分析。目标竞争对手的市场分析可以从基于技术的分析到市场组合策略进行分析。我们可以按照您所需的格式和数据样式添加您需要的任意数量的竞争对手数据。我们的分析师团队还可以为您提供原始 Excel 文件数据透视表(事实手册)中的数据,或者可以帮助您根据报告中的数据集创建演示文稿。

Frequently Asked Questions

市场是基于 亞太淋巴水腫治療市場細分,依治療類型(壓迫療法、手術、藥物療法、雷射療法等)、類型(繼發性淋巴水腫和原發性淋巴水腫)、患處(下肢、上肢及生殖器)、年齡組(成人、老年及兒童)、給藥途徑(口服、注射及外用)、最終用戶(院內、專科診所、門診手術至 203 年市場(203 年)。 进行细分的。
在2024年,亞太淋巴水腫治療市場的规模估计为136.19 USD Million美元。
亞太淋巴水腫治療市場预计将在2025年至2032年的预测期内以CAGR 12.8%的速度增长。
市场上的主要参与者包括Tactile Medical (U.S.) ,Essity Aktiebolag (publ) (Sweden) ,3M (U.S.) ,Cardinal Health (U.S.) ,Lohmann & Rauscher GmbH & Co. KG。
Testimonial